Indonesia to offer 80/160-year building (HGB) permits in IKN Nusantara to incentivise investment ACN Newswire

Indonesia to offer 80/160-year building (HGB) permits in IKN Nusantara to incentivise investment

October 14, 2022
JAKARTA, Oct 14, 2022 - (ACN Newswire via SEAPRWire.com) - Indonesia's Ministry of Agrarian Affairs and Spatial Planning/National Land Agency (ATR/BPN) is offering building use permits (HGBs) of up to 80 years, extendable to 160 years, as an incentive for investors to join in the construction of the Indonesian new capital (IKN) Nusantara, to be built in Samarinda, East Kalimantan.Balang Island Short Span Bridge connecting the IKN in Penajam, North Paser Regency, East Kalimantan (ANTARA/HO-ATR BPN/rst)Minister of Agrarian & Spatial Planning (ATR) and head of National Land Agency (BPN), Hadi Tjahjanto. (ANTARA/HO-ATR BPN/rst)"The HGB permits will benefit all parties, both the welfare of those who live in the city, and the business actors themselves," ATR Minister and BPN head Hadi Tjahjanto said to Antara here on Monday. The 80-year HGB will be divided into three stages: the first phase will span 30 years, the second phase 30 years, and the third phase 20 years.During the first stage, the investor must submit an assessment report, after which the "The permit will continue up to 80 years," said Hadi, and can be extended if it is productive for the community. "If it is still used properly and beneficially for the community, we can still extend it for another 80 years, up to 160 years," the minister informed.He further said that his ministry has completed four regional spatial planning plans (RDTR) for IKN Nusantara, which will be submitted to the IKN Authority for immediate approval. Furthermore, RDTRs are being prepared for the five regions of IKN Nusantara and are targeted to be completed by the end of 2022.The ministry will provide facilities related to land, spatial planning, and business licensing in the IKN Nusantara area, which will then be submitted to the IKN Authority. "We will facilitate it, and we will hand it over to the head of the IKN Authority, including RDTR, spatial planning, and land issues. We will help the process," Hadi said.The IKN Nusantara Authority is preparing a government regulation draft (RPP) on incentives for business, to make it easier to invest in the new capital city, while another measure will be preparing an IKN Authority-owned enterprise (BUMO). The IKN Authority will carry out market sounding of domestic and international investors later in October.A number of Asian countries have shown interest in the development of the new Indonesian capital (IKN) Nusantara. Japan, China, Malaysia, Australia, Hong Kong, and South Korea have all evinced an interest in investment, East Kalimantan Governor Isran Noor has disclosed.Earlier this year, President Joko Widodo said, "The new capital city is not merely a move of government offices. The goal is to build a new smart city that is competitive at the global level. Building a new locomotive for the transformation of Indonesia into an Indonesia based on innovation, technology, green economy. This is where we will start." See the original article: https://en.antaranews.com/news/254193/Written by: Rini Utami, Aditya Ramadhan, Resinta S, Editor: Suharto (c) ANTARA 2022 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
80-160 year building use rights in IKN to attract investors: Minister ACN Newswire

80-160 year building use rights in IKN to attract investors: Minister

October 12, 2022
JAKARTA, Oct 12, 2022 - (ACN Newswire via SEAPRWire.com) - The Ministry of Agrarian and Spatial Planning/National Land Agency (ATR/BPN) is offering building use rights (HGB) of up to 80 and extendable to 160 years to attract investors to the new capital (IKN) Nusantara.Balang Island Short Span Bridge in Penajam North Paser Regency, East Kalimantan (ANTARA/HO-ATR BPN/rst)"The efforts will benefit all parties, both to the welfare of those who live in the city or the business actors themselves," ATR Minister and BPN head, Hadi Tjahjanto, said to Antara here on Monday evening.The 80-year HGB permit is meant as an incentive for investors to invest in IKN Nusantara, he added. The 80-year HGB will be divided into three stages: the first phase will span 30 years, the second phase 30 years, and the third phase 20 years.In the first phase, the ministry will ask the investor to submit a report assessment. "The permit will continue up to 80 years," he said. The permit can be extended if it is profitable to the community. "If it is still used properly and beneficial to the community, we can still extend it for another 80 years, up to 160 years," the minister informed.He further said that his ministry has completed four regional spatial planning plans (RDTR) for IKN Nusantara, which will be submitted to the IKN Authority for immediate approval. Furthermore, RDTRs are being prepared for five regions and are targeted to be completed by the end of 2022.The ministry will provide facilities related to land, spatial planning, and business licensing in the IKN Nusantara area, which will then be submitted to the IKN Authority, he stated."We will facilitate it, and we will hand it over to the head of the IKN Authority, including RDTR, spatial planning, and land issues. We will help the process," he added.Written by: Rini Utami, Aditya Ramadhan, Resinta S, Editor: Suharto (c) ANTARA 2022 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
F.C.C. TSR Honda France Fights Back to Win Second FIM Endurance World Championship Title JCN Newswire

F.C.C. TSR Honda France Fights Back to Win Second FIM Endurance World Championship Title

September 19, 2022
Le Castellet, France, Sep 19, 2022 - (JCN Newswire via SEAPRWire.com) - F.C.C. TSR Honda France, running second in the 2022 FIM* Endurance World Championship (EWC), made a comeback to win this year's championship in the final round, the Bol d'Or 2022, held at Circuit Paul Ricard on September 17 - 18. The team has won the title for the second time, its first in the 2017-2018 season.F.C.C. TSR Honda France kicked off its 2022 campaign with riders Josh Hook (29 years old, Australia), Geno Rea (33 years old, UK) and Mike Di Meglio (24 years old, France) on a Honda CBR1000RR-R FIREBLADE SP.In the season-opener, the 24 Heures Motos held at Le Mans, the team qualified third, and finished third. In Round 2, the 24H SPA EWC Motos, the team started fourth on the Circuit de Spa-Francorchamps grid, and although down to tenth place mid-race, made a dramatic comeback to fourth, and a last lap charge by Rea gave them third in the final results.In Round 3, the Suzuka 8 Hours, held for the first time in three years, Rea crashed during free practice and was transported by helicopter to a hospital. Hook and Di Meglio was left to ride the eight-hour classic at the Suzuka Circuit in Mie. They qualified fourth, and although they faced numerous problems throughout the race, reclaimed places and finished tenth.F.C.C. TSR Honda France headed into the final round, the Bol d'Or 2022, second overall, 23 points behind the series leader. Alan Techer (28 years old, France), one of the riders in the team's previous victory in 2017-2018, stood in for Rea, in the hope that his experience will help them reclaim the title. The team started from fourth on the grid at 3:00 pm on the 17th. Two incidents sent their placing down to 28th, but consistent and determined riding brought the team back up to 4th place by the time the race ended at 3:00 pm on the 18th. As other championship contenders fail to complete the race, F.C.C. TSR Honda France won the overall championship.Josh Hook | F.C.C. TSR Honda France"I have learned from the past to never take a result for granted before the chequered flag. We have come back from complicated situations in the past and nothing is ever certain. Like everyone else, we did our race and never gave up. We did very well, all three of us were fast, especially at night. We were quickly no longer in a position to fight for victory, so we focused on the championship, which was clearly the priority goal. We chose to take care of the engine as much as possible to avoid the problems that most of our competitors have. And it's done!"Mike Di Meglio | F.C.C. TSR Honda France"I'm very happy to finally be World Endurance Champion! I came so close with GMT94 and I'm really proud of this title after so many years of fighting for it. It was a really tough race. We had some problems and our opponents were forced to stop one after the other. When Tati Team #4 was fighting at the front, we decided to build up enough of a gap to our chaser to get out of trouble. But when they dropped down the rankings, we changed our strategy to preserve the engine as much as possible by shifting earlier on the straight. It was the best thing to do because the world championship was more important than a podium finish."Alan Techer | F.C.C. TSR Honda France"It was a complicated race for everyone, we also had some mechanical problems. The team worked hard to reduce the time spent in the pits and, with my teammates, we did our best to respect the race plan. The objective was clearly the title, and after the Suzuki's retirement, we battled with the Tati Team, my former team. This is a special emotion for me, because I win this title with the team that had already given me the chance to be champion in 2018. We also have a big thought for Gino to whom we dedicate this title."* FIM: Federation Internationale de Motocyclisme Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
Therapeutic Goods Administration Grants Provisional Approval for Moderna’s COVID-19 Vaccine in Children Aged Six Months to Five Years ACN Newswire

Therapeutic Goods Administration Grants Provisional Approval for Moderna’s COVID-19 Vaccine in Children Aged Six Months to Five Years

July 19, 2022
Cambridge, MA, Jul 19, 2022 - (ACN Newswire via SEAPRWire.com) - Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional registration for the use of Moderna's mRNA COVID-19 vaccine, Spikevax, in a two-dose series of 25 ug per dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6 months to 5 years. Until now, children under six were the only age group not eligible for vaccination against COVID-19 in Australia."We are pleased that our vaccine for children under six years of age has received provisional approval by the TGA," said Michael Azrak, General Manager of Moderna for Australia and New Zealand. "The continued evolution of COVID-19 represents an emergent threat to global public health, including young children. Since the onset of the pandemic, we have worked with a deep sense of responsibility to deliver on the promise of mRNA science to all Australians. The approval from TGA helps extend an opportunity to all parents and caregivers in Australia to protect their young children against SARS-COV-2."Positive interim results from the Phase 2/3 KidCOVE study, announced on March 23, 2022, showed a robust neutralizing antibody response in the 6-month to 5 years of age group after a two-dose primary series of mRNA-1273, along with a favorable safety profile. The antibody titers in the pre-specified 6 month to 23 month and 2 years to 5 years of age sub-groups met the statistical criteria for similarity to the adults in the COVE study, which satisfied the primary objective of the study. Preliminary efficacy analysis on PCR-confirmed cases collected during the Omicron wave showed similar efficacy estimates against Omicron in the 6-month to 5 years of age group to those in adults after two doses of mRNA-1273.The KidCOVE study is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. The ClinicalTrials.gov identifier is NCT04796896.Moderna is committed to supporting the Australian Government on the COVID-19 program implementation in children aged 6 months to five years upon receiving a recommendation from the Australian Technical Advisory Group on Immunisation (ATAGI).The TGA previously approved the use of Moderna's mRNA COVID-19 vaccine, Spikevax (elasomeran mRNA vaccine), for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged six years or over.Authorized UseTherapeutic Goods Administration has provisionally approved the use of Moderna's mRNA COVID-19 vaccine, Spikevax (elasomeran mRNA vaccine), for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older.About ModernaIn 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both ground-breaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most-effective vaccines against the COVID-19 pandemic.Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.Forward Looking StatementsThis post contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the development of the Company's COVID-19 Vaccine (mRNA-1273, or Spikevax); the approval of the vaccine in children ages 6 months to 5 years by the Therapeutic Goods Administration; and the safety, efficacy, and tolerability of the vaccine in children ages 6 months to 5 years of age. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading "Risk Factors" in Moderna's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this post in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date hereof.Moderna ContactsMedia:Luke Mircea-WillatsDirector, Media Relations & CommunicationsLuke.mirceawillats@modernatx.comInvestors:Lavina TalukdarSenior Vice President & Head of Investor Relations617-209-5834Lavina.Talukdar@modernatx.comSOURCE: Moderna, Inc. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More